Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multi-specific therapeutic
Biotech
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
AbbVie is paying $700 million for a next-generation rival to J&J's Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma.
Nick Paul Taylor
Jul 10, 2025 9:01am
Daiichi gins up antibody research collab with German institute
Jan 14, 2025 3:44pm
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 10:00am
Purple snags Immunorizon's tri-specific antibodies in small M&A
Feb 2, 2023 10:20am
Amgen avoids 'low-hanging fruit' in tackling undruggable targets
Jun 29, 2022 3:00pm
Amgen targets 'multi-specifics' in drug development's 4th wave
Nov 4, 2021 11:37am
